Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 1
2005 1
2006 1
2007 1
2008 2
2010 4
2011 7
2012 5
2013 2
2014 3
2015 7
2016 6
2017 5
2018 4
2019 3
2020 6
2021 6
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "BRCA-Associated Ovarian Carcinoma"
Page 1
Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
Bellcross CA. Bellcross CA. Obstet Gynecol Clin North Am. 2022 Mar;49(1):117-147. doi: 10.1016/j.ogc.2021.11.005. Obstet Gynecol Clin North Am. 2022. PMID: 35168766 Review.
This article provides an update on hereditary breast and ovarian cancer syndrome (HBOC) associated with pathogenic variants (PVs) in BRCA1/2. While many new genes have been identified and are included in testing panels, HBOC will serve as the primary example to illustrate …
This article provides an update on hereditary breast and ovarian cancer syndrome (HBOC) associated with pathogenic variants (PVs) in …
Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Militaru FC, Militaru V, Crisan N, Bocsan IC, Udrea AA, Catana A, Kutasi E, Militaru MS. Militaru FC, et al. Biomol Biomed. 2023 Sep 4;23(5):760-771. doi: 10.17305/bb.2023.8782. Biomol Biomed. 2023. PMID: 37021836 Free PMC article. Review.
The most common genetic syndromes associated with prostate cancer risk are BRCA-associated hereditary breast and ovarian cancer (HBOC) and Lynch syndrome. ...
The most common genetic syndromes associated with prostate cancer risk are BRCA-associated hereditary breast and ovarian …
Olaparib.
Goulooze SC, Cohen AF, Rissmann R. Goulooze SC, et al. Br J Clin Pharmacol. 2016 Jan;81(1):171-3. doi: 10.1111/bcp.12761. Epub 2015 Oct 24. Br J Clin Pharmacol. 2016. PMID: 26344419 Free PMC article.
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in …
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Ol …
BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management.
Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO. Lee MV, et al. Radiographics. 2017 Jul-Aug;37(4):1005-1023. doi: 10.1148/rg.2017160144. Epub 2017 May 26. Radiographics. 2017. PMID: 28548905 Review.
Imaging has an important role in the screening, evaluation, staging, and follow-up of BRCA-associated malignancies. Supplemental screening of BRCA mutation carriers often begins at an early age and is critical for early and accurate cancer diagnoses. The authors rev …
Imaging has an important role in the screening, evaluation, staging, and follow-up of BRCA-associated malignancies. Supplement …
Olaparib in the treatment of ovarian cancer.
Washington CR, Richardson DL, Moore KN. Washington CR, et al. Future Oncol. 2019 Oct;15(30):3435-3449. doi: 10.2217/fon-2019-0271. Epub 2019 Sep 3. Future Oncol. 2019. PMID: 31478762 Review.
The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-associated epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond. ...Once recurrent, the …
The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-associated epithelial ovarian cancer ( …
BRCA1/2 reversion mutations in a pan-cancer cohort.
Nakamura K, Hayashi H, Kawano R, Ishikawa M, Aimono E, Mizuno T, Kuroda H, Kojima Y, Niikura N, Kawanishi A, Takeshita K, Suzuki S, Ueno S, Okuwaki K, Sasaki J, Yamaguchi M, Masuda K, Chiyoda T, Yamagami W, Okada C, Nohara S, Tanishima S, Nishihara H. Nakamura K, et al. Cancer Sci. 2024 Feb;115(2):635-647. doi: 10.1111/cas.16033. Epub 2023 Dec 1. Cancer Sci. 2024. PMID: 38041241 Free PMC article.
We identified 12 (0.32%) patients with somatic BRCA1 (n = 3) and BRCA2 (n = 9) reversion mutations in breast (n = 4), ovarian/fallopian tube/peritoneal (n = 4), pancreatic (n = 2), prostate (n = 1), and gallbladder (n = 1) cancers. ...Disease course data were obtained for …
We identified 12 (0.32%) patients with somatic BRCA1 (n = 3) and BRCA2 (n = 9) reversion mutations in breast (n = 4), ovarian/fallopi …
Genetic predisposition in gynecologic cancers.
Daniels MS, Lu KH. Daniels MS, et al. Semin Oncol. 2016 Oct;43(5):543-547. doi: 10.1053/j.seminoncol.2016.08.005. Epub 2016 Sep 20. Semin Oncol. 2016. PMID: 27899185 Review.
This review article discusses the diagnosis and management of hereditary ovarian cancer and hereditary uterine cancer. The key recommendations highlighted are: All women with high grade non-mucinous epithelial ovarian cancer should be offered at least BRCA1 and BRCA …
This review article discusses the diagnosis and management of hereditary ovarian cancer and hereditary uterine cancer. The key recomm …
Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers.
Shaw PA, Clarke BA. Shaw PA, et al. Surg Pathol Clin. 2016 Jun;9(2):307-28. doi: 10.1016/j.path.2016.02.002. Surg Pathol Clin. 2016. PMID: 27241111 Review.
Hereditary breast ovarian cancer and Lynch/hereditary nonpolyposis colorectal cancer syndrome account for most hereditary gynecologic cancers. In the absence of effective cancer screening and other preventative strategies, risk-reducing surgery in women who are known to be …
Hereditary breast ovarian cancer and Lynch/hereditary nonpolyposis colorectal cancer syndrome account for most hereditary gynecologic …
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.
van Barele M, Akdeniz D, Heemskerk-Gerritsen BAM; Genepso; Andrieu N, Noguès C; HEBON; van Asperen CJ, Wevers M, Ausems MGEM, de Bock GH, Dommering CJ, Gómez-García EB, van Leeuwen FE, Mooij TM; EMBRACE; Easton DF, Antoniou AC, Evans DG, Izatt L, Tischkowitz M, Frost D, Brewer C, Olah E, Simard J, Singer CF, Thomassen M, Kast K, Rhiem K, Engel C, de la Hoya M, Foretová L, Jakubowska A, Jager A, Sattler MGA, Schmidt MK, Hooning MJ. van Barele M, et al. J Natl Cancer Inst. 2023 Nov 8;115(11):1318-1328. doi: 10.1093/jnci/djad116. J Natl Cancer Inst. 2023. PMID: 37369040 Free PMC article.
BACKGROUND: Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), especially in young patients with germline (g)BRCA-associated BC who already have high contralateral BC (CBC) risk and potential …
BACKGROUND: Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), es …
PARP inhibition as frontline therapy in ovarian cancer.
Moore KN, Pothuri B, Monk B, Coleman RL. Moore KN, et al. Clin Adv Hematol Oncol. 2020 Sep;18(9):550-556. Clin Adv Hematol Oncol. 2020. PMID: 33006584 Review.
Poly(ADP-ribose) polymerase (PARP) inhibitors have been rapidly integrated into clinical practice for women with ovarian cancer. Currently, PARP inhibitors are approved as frontline maintenance treatment for patients with and without BRCA-associated cancers, …
Poly(ADP-ribose) polymerase (PARP) inhibitors have been rapidly integrated into clinical practice for women with ovarian cancer. Curr …
63 results